Cargando…

Hot Melt Coating of Amorphous Carvedilol

The use of amorphous drug delivery systems is an attractive approach to improve the bioavailability of low molecular weight drug candidates that suffer from poor aqueous solubility. However, the pharmaceutical performance of many neat amorphous drugs is compromised by their tendency for recrystalliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Bannow, Jacob, Koren, Lina, Salar-Behzadi, Sharareh, Löbmann, Korbinian, Zimmer, Andreas, Rades, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356097/
https://www.ncbi.nlm.nih.gov/pubmed/32517255
http://dx.doi.org/10.3390/pharmaceutics12060519
_version_ 1783558421003370496
author Bannow, Jacob
Koren, Lina
Salar-Behzadi, Sharareh
Löbmann, Korbinian
Zimmer, Andreas
Rades, Thomas
author_facet Bannow, Jacob
Koren, Lina
Salar-Behzadi, Sharareh
Löbmann, Korbinian
Zimmer, Andreas
Rades, Thomas
author_sort Bannow, Jacob
collection PubMed
description The use of amorphous drug delivery systems is an attractive approach to improve the bioavailability of low molecular weight drug candidates that suffer from poor aqueous solubility. However, the pharmaceutical performance of many neat amorphous drugs is compromised by their tendency for recrystallization during storage and lumping upon dissolution, which may be improved by the application of coatings on amorphous surfaces. In this study, hot melt coating (HMC) as a solvent-free coating method was utilized to coat amorphous carvedilol (CRV) particles with tripalmitin containing 10% (w/w) and 20% (w/w) of polysorbate 65 (PS65) in a fluid bed coater. Lipid coated amorphous particles were assessed in terms of their physical stability during storage and their drug release during dynamic in vitro lipolysis. The release of CRV during in vitro lipolysis was shown to be mainly dependent on the PS65 concentration in the coating layer, with a PS65 concentration of 20% (w/w) resulting in an immediate release profile. The physical stability of the amorphous CRV core, however, was negatively affected by the lipid coating, resulting in the recrystallization of CRV at the interface between the crystalline lipid layer and the amorphous drug core. Our study demonstrated the feasibility of lipid spray coating of amorphous CRV as a strategy to modify the drug release from amorphous systems but at the same time highlights the importance of surface-mediated processes for the physical stability of the amorphous form.
format Online
Article
Text
id pubmed-7356097
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73560972020-07-31 Hot Melt Coating of Amorphous Carvedilol Bannow, Jacob Koren, Lina Salar-Behzadi, Sharareh Löbmann, Korbinian Zimmer, Andreas Rades, Thomas Pharmaceutics Article The use of amorphous drug delivery systems is an attractive approach to improve the bioavailability of low molecular weight drug candidates that suffer from poor aqueous solubility. However, the pharmaceutical performance of many neat amorphous drugs is compromised by their tendency for recrystallization during storage and lumping upon dissolution, which may be improved by the application of coatings on amorphous surfaces. In this study, hot melt coating (HMC) as a solvent-free coating method was utilized to coat amorphous carvedilol (CRV) particles with tripalmitin containing 10% (w/w) and 20% (w/w) of polysorbate 65 (PS65) in a fluid bed coater. Lipid coated amorphous particles were assessed in terms of their physical stability during storage and their drug release during dynamic in vitro lipolysis. The release of CRV during in vitro lipolysis was shown to be mainly dependent on the PS65 concentration in the coating layer, with a PS65 concentration of 20% (w/w) resulting in an immediate release profile. The physical stability of the amorphous CRV core, however, was negatively affected by the lipid coating, resulting in the recrystallization of CRV at the interface between the crystalline lipid layer and the amorphous drug core. Our study demonstrated the feasibility of lipid spray coating of amorphous CRV as a strategy to modify the drug release from amorphous systems but at the same time highlights the importance of surface-mediated processes for the physical stability of the amorphous form. MDPI 2020-06-06 /pmc/articles/PMC7356097/ /pubmed/32517255 http://dx.doi.org/10.3390/pharmaceutics12060519 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bannow, Jacob
Koren, Lina
Salar-Behzadi, Sharareh
Löbmann, Korbinian
Zimmer, Andreas
Rades, Thomas
Hot Melt Coating of Amorphous Carvedilol
title Hot Melt Coating of Amorphous Carvedilol
title_full Hot Melt Coating of Amorphous Carvedilol
title_fullStr Hot Melt Coating of Amorphous Carvedilol
title_full_unstemmed Hot Melt Coating of Amorphous Carvedilol
title_short Hot Melt Coating of Amorphous Carvedilol
title_sort hot melt coating of amorphous carvedilol
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356097/
https://www.ncbi.nlm.nih.gov/pubmed/32517255
http://dx.doi.org/10.3390/pharmaceutics12060519
work_keys_str_mv AT bannowjacob hotmeltcoatingofamorphouscarvedilol
AT korenlina hotmeltcoatingofamorphouscarvedilol
AT salarbehzadisharareh hotmeltcoatingofamorphouscarvedilol
AT lobmannkorbinian hotmeltcoatingofamorphouscarvedilol
AT zimmerandreas hotmeltcoatingofamorphouscarvedilol
AT radesthomas hotmeltcoatingofamorphouscarvedilol